Program
TQH2722
A development code. Also written as “TQH2722 injection”, “300mg of TQH2722 injection” and “600mg of TQH2722 injection”.
In Sino Biopharmaceutical's pipeline, IL-4Rα单抗
. Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Sinusitis · Rhinosinusitis, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 71 open or running | phase 3since Aug 8, 2024 | May 24, 2022 | Nov 2026phase 2 · NCT07398859 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQH2722
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 24, 2022First study: phase 1 study in Dermatitis, AtopicFirst studyNCT05409326 · 48 enrolled · China
- Jul 24, 2023Phase 2 study in Dermatitis, AtopicNCT05970432 · 160 enrolled · China
- Oct 13, 2023Phase 2 study in SinusitisNCT06089278 · 160 enrolled · China
- May 28, 2024Phase 2 study in Chronic RhinosinusitisNCT06439381 · 119 enrolled · China
- Aug 8, 2024Phase 3 study in Dermatitis, AtopicNCT06552520 · 500 enrolled · China
- Dec 25, 2024Phase 2 study in Rhinitis, Allergic, SeasonalNCT06760182 · 169 enrolled · China
- Feb 3, 2026Phase 2 study in Rhinitis, Allergic, SeasonalNCT07398859 · 300 planned · China
Ahead
- Nov 2026Primary completion: phase 2 study in Rhinitis, Allergic, SeasonalNCT07398859
TargetBeta
“IL-4Rα单抗”the company's pipeline, read by Claude · source
Other programs on IL4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dupilumabrule | Sanofi | phase 4 | 93 |
| drotokibart | Jiangsu HengRui Medicine | phase 3 | 8 |
| SHR-1819 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07398859Rhinitis, Allergic, Seasonal · China | 2 | Recruiting | Nov 2026 | 300 |
| NCT06760182Rhinitis, Allergic, Seasonal · China | 2 | Completed | Apr 30, 2025 | 169 |
| NCT06552520Dermatitis, Atopic · China | 3 | Completed | Sep 11, 2025 | 500 |
| NCT06439381Chronic Rhinosinusitis · China | 2 | Completed | Dec 19, 2025 | 119 |
| NCT06089278Sinusitis · China | 2 | Completed | Mar 30, 2025 | 160 |
| NCT05970432Dermatitis, Atopic · China | 2 | UNKNOWN | Mar 2024 | 160 |
| NCT05409326Dermatitis, Atopic · China | 1 | UNKNOWN | Jun 2023 | 48 |
How it is read
Names in the registry
- “TQH2722 injection”, 4 entries
- “300mg of TQH2722 injection”, 1 entry
- “600mg of TQH2722 injection”, 1 entry
- “300mg/600mg of TQH2722 injection”, 1 entry
- “TQH2722 injection 300mg-150mg”, 1 entry
Codes read as this program: TQH2722.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Rhinitis, Allergic, Seasonal, 2 studies
- Sinusitis, 1 study
- Rhinosinusitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.